Luis Pérez de Llano
A5081821302- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Inhalation and Respiratory Drug Delivery
- Respiratory Support and Mechanisms
- Allergic Rhinitis and Sensitization
- Delphi Technique in Research
- Obstructive Sleep Apnea Research
- IL-33, ST2, and ILC Pathways
- Neuroscience of respiration and sleep
- COVID-19 Clinical Research Studies
- Eosinophilic Esophagitis
- Pharmaceutical studies and practices
- Pneumonia and Respiratory Infections
- COVID-19 and Mental Health
- Long-Term Effects of COVID-19
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Air Quality and Health Impacts
- Sepsis Diagnosis and Treatment
- Family and Patient Care in Intensive Care Units
- Healthcare Systems and Technology
- Neuropeptides and Animal Physiology
- COVID-19 and healthcare impacts
- COVID-19 Digital Contact Tracing
- Food Allergy and Anaphylaxis Research
Hospital Universitario Lucus Augusti
2016-2025
Universidade de Santiago de Compostela
2024-2025
Instituto de Salud Carlos III
2024
Translational Research Institute
2021
Observational & Pragmatic Research Institute
2021
Universidade do Porto
2020
McMaster University
2020
Centre for Health Technology and Services Research
2020
St. Joseph’s Healthcare Hamilton
2020
Hospital Xeral Calde
2005-2013
Abstract Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care pathways differences between national or regional Better understanding of the mechanisms has enabled stratified approach management severe asthma, supporting use targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection certain...
Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are not well characterized in global, real-life severe cohorts.What is the prevalence phenotypes population asthma, can these be differentiated by clinical biomarker variables?This was an historical registry study. Adult available blood eosinophil count (BEC) from 11 countries enrolled International Severe Asthma Registry (January 1, 2015-September 30, 2019) were categorized according to likelihood phenotype...
Rationale: There is no consensus on criteria to include in an asthma remission definition real-life. Factors associated with achieving post-biologic-initiation remain poorly understood. Objectives: To quantify the proportion of adults severe multi-domain-defined and identify pre-biologic characteristics which may be used predict it. Methods: This was a longitudinal cohort study using data from 23 countries International Severe Asthma Registry. Four outcome domains were assessed 1-year pre-...
The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As first global registry for adults with asthma, ISAR enabled individual registries standardize pool their data, creating a comprehensive, harmonized dataset sufficient statistical power address key research questions knowledge gaps. Today, is largest repository real-world data on curating nearly 35,000 patients...
Aim To study whether mortality and cardiovascular morbidity differ in non-invasive ventilation (NIV)-treated patients with severe obesity-hypoventilation syndrome (OHS) as compared CPAP-treated obstructive sleep apnea (OSAS), to identify independent predictors of OHS. Material methods Two retrospective cohorts OHS OSAS were matched 1:2 according sex, age (±10 year) length time since initiation CPAP/NIV therapy (±6 months). Results Three hundred thirty subjects (110 220 OSAS) studied. Mean...
Aim. To evaluate the effectiveness of omalizumab in non-atopic asthma. Methods. Using data from a multicenter registry severe asthma, we evaluated and compared clinical outcome 29 omalizumab-treated asthmatics with 266 allergic asthmatics. Effectiveness was assessed by considering exacerbations, pulmonary function, Global Evaluation Treatment (GETE) scale, Asthma Control Test (ACT). Results. Omalizumab demonstrated significant improvement status as measured GETE, which rose 1.6 ± 1.1 to 2.8...
Allergy, eosinophilic inflammation, and epithelial dysregulation are implicated in severe asthma pathogenesis.We characterized biomarker expression adults with asthma.Within the International Severe Asthma Registry (ISAR), we analyzed data from 10 countries North America, Europe, Asia, prespecified thresholds for positivity (serum IgE ≥ 75 kU/L, blood eosinophils 300 cells/μL, FeNO 25 ppb), hierarchical cluster analysis using biomarkers as continuous variables.Of 1,175 patients; 64% were...
International registries provide opportunities to describe use of biologics for treating severe asthma in current clinical practice. Our aims were real-life global patterns biologic (continuation, switches, and discontinuations) asthma, elucidate reasons underlying these patterns, examine associated patient-level factors.This was a historical cohort study including adults with enrolled into the Severe Asthma Registry (ISAR; http://isaregistries.org, 2015-2020) or CHRONICLE Study (2018-2020)...
BackgroundInvestigation for the presence of asthma comorbidities is recommended by GINA as their can complicate management.ObjectiveTo understand prevalence and pattern multimorbidity in adults with severe association asthma-related outcomes.MethodsThis was a cross-sectional study using data from International Severe Asthma Registry 22 countries. Thirty were identified categorized priori either (1) potentially T2-related, (2) oral corticosteroid (OCS)-related or (3) mimicking/aggravating...
Background To date, studies investigating the association between pre-biologic biomarker levels and post-biologic outcomes have been limited to single biomarkers assessment of biologic efficacy from structured clinical trials. Aim elucidate associations individual or their combinations with pre-to-post changes in asthma real-life. Methods This was a registry-based, cohort study using data 23 countries, which shared International Severe Asthma Registry (May 2017-February 2023). The...
The efficacy of omalizumab in severe asthma has been widely demonstrated. main objective this study was to evaluate the and tolerability a real-life setting Spain, particularly those patients with immunoglobulin E (IgE) levels out range.Totally 266 uncontrolled receiving high-dose inhaled corticosteroids (ICSs) plus long-acting β2-agonist (LABA) were recruited. Main outcomes exacerbation rate (AER), control test (ACT), global evaluation treatment effectiveness (GETE).AER reduced from 3.6...
BACKGROUND Effectiveness of biologics has neither been established in patients with high oral corticosteroid exposure (HOCS), nor compared to effectiveness continuing HOCS alone. OBJECTIVE To examine the initiating a large, real-world cohort adult severe asthma and HOCS. METHODS This was propensity-score-matched, prospective study using data from International Severe Asthma Registry (http://isaregistries.org/). Between January 2015 February 2021, (long-term OCS ≥1 year or ≥4 courses rescue...
Patients with severe asthma may present characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile adult patients both anti-IgE and anti-IL5/5R compare effectiveness classes treatment in real life.This a prospective cohort study that included from 22 countries enrolled into International Severe Asthma registry (ISAR) who were anti-IL5/5R. The compared 1:1 matched cohort. Exacerbation rate primary...
What is already known about the topic? Response to biologics variable, partly due inclusion of different outcomes in response definitions (e.g. exacerbations, long-term corticosteroid dose, symptom control, lung function). Identifying those most likely respond real-life has proven challenging. does this article add our knowledge? and their predictors vary according outcome assessed. A greater pre-biologic impairment associated with better for all However shorter asthma duration function...
<i>Background:</i> Obesity hypoventilation syndrome (OHS) can be treated with noninvasive positive pressure ventilation (NIPPV). Once clinical stability is achieved, continuous airway (CPAP) recommended in many cases. However, some patients respond only partially to CPAP and NIPPV a better option for them. <i>Objectives:</i> To assess treatment effectiveness 2 groups of patients: those who could switched after polysomnographic titration required NIPPV....
Purpose: Grouping COPD subjects into clinical phenotypes might be useful for the management of disease, but implications such classification are still not totally clear, especially regarding prognosis. The primary objective this study was to assess whether mortality rates were different between four predefined phenotypes. Patients and methods: This is a retrospective, observational carried out at clinic University Hospital. A total 891 patients classified, according Spanish guidelines,...